Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

Pooja M. Phull; Carlyn R. Tan; Henry C. Fung; Paul A. Fields; Yang Liu; Jasmine Zain; Nathan H. Fowler; R. Katherine Alpaugh; Yasuhiro Oki; Stefan K. Barta

doi:10.21037/pcm-20-45

Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

Pooja M. Phull, Carlyn R. Tan, Henry C. Fung, Paul A. Fields, Yang Liu, Jasmine Zain, Nathan H. Fowler, R. Katherine Alpaugh, Yasuhiro Oki, Stefan K. Barta

Lymphoma-Myeloma

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Article number	31
Journal	Precision Cancer Medicine
Volume	3
Issue number	December
DOIs	https://doi.org/10.21037/pcm-20-45
State	Published - Dec 2020

ASJC Scopus subject areas

Oncology
Cancer Research
Oncology(nursing)
Pharmacology (medical)
Surgery
Anesthesiology and Pain Medicine

Access to Document

10.21037/pcm-20-45

Cite this

@article{c32bc19c970144ffbf47e0ccdf8218c4,

title = "Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma",

author = "Phull, {Pooja M.} and Tan, {Carlyn R.} and Fung, {Henry C.} and Fields, {Paul A.} and Yang Liu and Jasmine Zain and Fowler, {Nathan H.} and Alpaugh, {R. Katherine} and Yasuhiro Oki and Barta, {Stefan K.}",

note = "Funding Information: Peer Review File: Available at http://dx.doi.org/10.21037/ pcm-20-45 Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/pcm-20-45). HCF reports personal fees from Genetech , personal fees from Sandofi, personal fees from Astrazeneca, personal fees from Abbvie, personal fees from Amgen, personal fees from Takada , personal fees from Jansen , personal fees from BMS, personal fees from Karyopharm, outside the submitted work. PAF is an employee at Adaptive Biotechnologies. JZ reports personal fees from Seattle genetics, verastem, kiyowa Kirin, and Mundi pahrma, outside the submitted work. NHF reports personal fees from Bostongene, during the conduct of the study; grants from Roche, grants and personal fees from Gilead, grants and personal fees from TG Therapeutics, outside the submitted work. YO reports other support from Genentech, outside the submitted work. SKB reports grants from Merck, during the conduct of the study; grants and personal fees from Seattle Genetics, grants from Celgene, grants from Bayer, personal fees from Atara, personal fees from Mundipharma, personal fees from Pfizer, outside the submitted work. And SKB serves as an unpaid editorial board member of Precision Cancer Medicine from Jun 2020 to May 2022. The other authors have no conflicts of interest to declare.",

year = "2020",

month = dec,

doi = "10.21037/pcm-20-45",

language = "English (US)",

volume = "3",

journal = "Precision Cancer Medicine",

issn = "2617-2216",

publisher = "AME Publishing Company",

number = "December",

}

TY - JOUR

T1 - Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

AU - Phull, Pooja M.

AU - Tan, Carlyn R.

AU - Fung, Henry C.

AU - Fields, Paul A.

AU - Liu, Yang

AU - Zain, Jasmine

AU - Fowler, Nathan H.

AU - Alpaugh, R. Katherine

AU - Oki, Yasuhiro

AU - Barta, Stefan K.

N1 - Funding Information: Peer Review File: Available at http://dx.doi.org/10.21037/ pcm-20-45 Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/pcm-20-45). HCF reports personal fees from Genetech , personal fees from Sandofi, personal fees from Astrazeneca, personal fees from Abbvie, personal fees from Amgen, personal fees from Takada , personal fees from Jansen , personal fees from BMS, personal fees from Karyopharm, outside the submitted work. PAF is an employee at Adaptive Biotechnologies. JZ reports personal fees from Seattle genetics, verastem, kiyowa Kirin, and Mundi pahrma, outside the submitted work. NHF reports personal fees from Bostongene, during the conduct of the study; grants from Roche, grants and personal fees from Gilead, grants and personal fees from TG Therapeutics, outside the submitted work. YO reports other support from Genentech, outside the submitted work. SKB reports grants from Merck, during the conduct of the study; grants and personal fees from Seattle Genetics, grants from Celgene, grants from Bayer, personal fees from Atara, personal fees from Mundipharma, personal fees from Pfizer, outside the submitted work. And SKB serves as an unpaid editorial board member of Precision Cancer Medicine from Jun 2020 to May 2022. The other authors have no conflicts of interest to declare.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85110747512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110747512&partnerID=8YFLogxK

U2 - 10.21037/pcm-20-45

DO - 10.21037/pcm-20-45

M3 - Letter

AN - SCOPUS:85110747512

SN - 2617-2216

VL - 3

JO - Precision Cancer Medicine

JF - Precision Cancer Medicine

IS - December

M1 - 31

ER -

Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this